Takeda Stresses Orexin Commitment Despite Setback
Big Share Buyback As Q2 Reported
Executive Summary
Fiscal Q2 figures in line with expectations but investors digest surprise trial halt and share buyback.
You may also be interested in...
Takeda Hits Accelerator On TAK-861 After Phase II Narcolepsy Win
The drug maker plans to move the drug into Phase III development for NT1, though it appears to have missed on NT2. But a lack of key toxicities may bode well for the orexin agonist class too.
A Year And A Half After Giving Up On TAK-721, Takeda Seeks Approval In EoE
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.
Deal Watch: Novo Nordisk Links With Flagship To Create Cardiometabolic, Rare Disease Portfolio
The Danish diabetes titan teams with Moderna’s founder on cardiometabolic R&D. Troubled cell therapy biotech Bone Therapeutics negotiates reverse merger with Medsenic.